Guggenheim Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Equities research analysts at Guggenheim assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $96.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 72.69% from the company’s current price.

Several other equities research analysts have also commented on KROS. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Bank of America decreased their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Oppenheimer assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Finally, Truist Financial restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Buy” and an average target price of $90.63.

Keros Therapeutics Stock Performance

Shares of KROS opened at $55.59 on Monday. The stock has a market capitalization of $2.01 billion, a P/E ratio of -10.76 and a beta of 1.22. The company’s fifty day moving average is $49.60 and its two-hundred day moving average is $52.86. Keros Therapeutics has a 1 year low of $27.02 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the prior year, the company earned ($1.27) earnings per share. Sell-side analysts predict that Keros Therapeutics will post -4.78 EPS for the current year.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at about $128,000. Ameritas Investment Partners Inc. increased its stake in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the last quarter. Quest Partners LLC increased its stake in shares of Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after acquiring an additional 4,789 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at about $228,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Keros Therapeutics during the 1st quarter valued at about $267,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.